Market Cap 12.17B
Revenue (ttm) 2.36B
Net Income (ttm) 341.30M
EPS (ttm) N/A
PE Ratio 42.22
Forward PE 32.88
Profit Margin 14.49%
Debt to Equity Ratio 0.00
Volume 833,400
Avg Vol 1,611,448
Day's Range N/A - N/A
Shares Out 98.97M
Stochastic %K 87%
Beta 0.26
Analysts Strong Sell
Price Target $161.08

Latest News on NBIX

Why Is Neurocrine Biosciences Stock Trading Lower On Friday?

Feb 7, 2025, 1:05 PM EST - 4 months ago

Why Is Neurocrine Biosciences Stock Trading Lower On Friday?


US FDA approves Neurocrine Biosciences' genetic disorder drug

Dec 13, 2024, 5:50 PM EST - 6 months ago

US FDA approves Neurocrine Biosciences' genetic disorder drug